Publications by authors named "Jonathan D Cheng"

Claim this Profile
C
Correction to: Resection of Isolated Pelvic Recurrences after Colorectal Surgery: Long-Term Results and Predictors of Improved Clinical Outcome.
Leonard R Henry, Elin Sigurdson, Eric A Ross, John S Lee, James C Watson, Jonathan D Cheng

Ann Surg Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Resection of Isolated Pelvic Recurrences after Colorectal Surgery: Long-Term Results and Predictors of Improved Clinical Outcome.
Leonard R Henry, Elin Sigurdson, Eric A Ross, John S Lee, James C Watson, Jonathan D Cheng

Ann Surg Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, Jose Dinis, Lisa F Licitra, Jonathan D Cheng

J Natl Cancer Inst· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Jonathan D Cheng

Lancet· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.
Mark Ayers, Michael Nebozhyn, Razvan Cristescu, Terrill K McClanahan, Rodolfo Perini, Jonathan D Cheng

Clin Cancer Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Janice M Mehnert, Andrea Varga, Marcia S Brose, Rahul R Aggarwal, Chia-Chi Lin, Jonathan D Cheng

BMC Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
Mallika Lala, Diana Chirovsky, Jonathan D Cheng, Kapil Mayawala

Oral Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
Makoto Tahara, Kei Muro, Yasuhisa Hasegawa, Hyun Cheol Chung, Chia-Chi Lin, Jonathan D Cheng

Cancer Sci· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B Cohen, Jonathan D Cheng

J Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Patrick M Boland, Joshua E Meyer, Adam C Berger, Steven J Cohen, Tzahi Neuman, Jonathan D Cheng

Am J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, Jonathan D Cheng

J Clin Invest· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, Francis Worden, Stephen V Liu, Jonathan D Cheng

J Clin Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Laura Q M Chow, Robert Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Jonathan D Cheng

J Clin Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Jonathan D Cheng

J Clin Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Tanguy Y Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Jonathan D Cheng

Lancet Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
Shilpa Gupta, Guillem Argilés, Pamela N Munster, Antoine Hollebecque, Olav Dajani, Jonathan D Cheng

Clin Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
Crystal S Denlinger, Neal J Meropol, Tianyu Li, Nancy L Lewis, Paul F Engstrom, Jonathan D Cheng

Clin Colorectal Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).
Koen Jansen, Leen Heirbaut, Robert Verkerk, Jonathan D Cheng, Jurgen Joossens

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma.
Lauren M Tait, Joshua E Meyer, Erin McSpadden, Jonathan D Cheng, Frank A Baciewicz

Pract Radiat Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.
Koen Jansen, Leen Heirbaut, Jonathan D Cheng, Jurgen Joossens, Oxana Ryabtsova

ACS Med Chem Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Jiping Zhang, Matthildi Valianou, Heidi Simmons, Matthew K Robinson, Hyung-Ok Lee, Jonathan D Cheng

FASEB J· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.
Pieter Van der Veken, Vilmos Fülöp, Dean Rea, Melanie Gerard, Roos Van Elzen, Jonathan D Cheng

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha.
Jinbo Li, Kai Chen, Hongguang Liu, Kai Cheng, Meng Yang, Jonathan D Cheng, Zhen Cheng

Bioconjug Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
Andre Konski, Tianyu Li, Michael Christensen, Jonathan D Cheng, Jian Q Yu

Radiother Oncol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
Oxana Ryabtsova, Koen Jansen, Sebastiaan Van Goethem, Jurgen Joossens, Jonathan D Cheng

Bioorg Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis